Clinicians with obligations to patients and to organizations often assess patients in law enforcement for both therapeutic and nontherapeutic purposes.
AMA J Ethics. 2022; 24(2):E111-119. doi:
10.1001/amajethics.2022.111.
Furthering clinicians’ understandings of how daily practice can respond to Black patients' experiences can help restore trust and mitigate racial and ethnic health inequity.
AMA J Ethics. 2021; 23(6):E480-486. doi:
10.1001/amajethics.2021.480.
This digital still from a narrated animated portrait depicts a woman overwhelmed by her body’s failure and by a health care system’s failure to care well.
AMA J Ethics. 2021; 23(8):E658-659. doi:
10.1001/amajethics.2021.658.
Dr Zoe Tao and Dr Michael Oldani join Ethics Talk to discuss how learning about transgenerational trauma can help clinicians motivate health equity, especially among historically marginalized groups like Native American and First Nations communities.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021; 23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Differentiating between best palliative care options and the curative and palliative potential of surgery is key to developing dual intentional clarity.
AMA J Ethics. 2021; 23(10):E766-771. doi:
10.1001/amajethics.2021.766.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"